# Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT04792593** · NA · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- B-ALL

## Interventions

- **BIOLOGICAL:** Senl-h19 CAR-T

## Key facts

- **NCT ID:** NCT04792593
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-03
- **Primary completion:** 2021-12-10
- **Final completion:** 2022-02-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792593, "Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04792593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*